Background. The rationale and lessons learned through the evolution of the National Survey for the Susceptibility of Bacteroides fragilis Group from its initiation in 1981 through 2007 are reviewed here. The survey was conceived in 1980 to track emerging antimicrobial resistance in Bacteroides species.
NOTE. The Principal Investigators of the study were Francis P. Tally (1981 Tally ( -1986 ), George J. Cuchural, Jr. (1986 -1990 , and David R. Snydman (1986 Snydman ( -2007 its beginning (Table 1 ). In the method used from 1981 through 1997, supplemented brain-heart infusion agar was given an inoculum of [7] . In 1997, the survey adopted the 6 1 ϫ 10 method recommended that year by the Clinical and Laboratory Standards Institute (CLSI; formerly, National Committee on Clinical Laboratory Standards); with this method, supplemented brucella blood agar used an inoculum of [8] . 8 1 ϫ 10 The antibiotics tested are listed in Table 1 . Over the last 27 years of the survey, the test antibiotics changed as newer agents were introduced. The agents that were continuously tested were clindamycin, cefoxitin, metronidazole, and chloramphenicol. Statistical analysis was first performed using a TRS/80 Model 1 computer from Radio Shack. There is some irony that contemporary wristwatches probably have more computing power than this early version of the TRS/80. Current analyses are performed using SAS, version 8.01, for Windows (SAS Institute).
In the early 1980s, among isolates of the Bacteroides species (which were analyzed as a group), 6% were resistant to clindamycin and 8% were resistant to cefoxitin [9, 10] . In contrast, by 2004, clindamycin resistance had increased to 31.6%, although cefoxitin resistance remained relatively constant at 8% [11] . Table 2 shows the changes in susceptibility that occurred over the 3 decades of the study.
The survey group has been responsible for 115 publications [6, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] , and a number of themes and principles have emerged. One is that the susceptibility of Bacteroides species to antimicrobials is important to outcome, even in the presence of mixed infections. For instance, in the context of Bacteroides bacteremia due to mixed infection, the survey group revealed that outcome and susceptibility are related [5] . The survey group has been instrumental in establishing susceptibility criteria for certain antibiotics for the CLSI. For drug development studies, the survey has provided a framework for activity that provides pharmaceutical companies with data for further clinical development [22] . In addition, the group has made major contributions toward the use of different media and testing methods [23] . For this symposium in honor of Frank Tally, MD, we analyzed the data on drug susceptibility of Bacteroides species from 1997 through 2007, to examine trends over time for certain drug and organism combinations, as well as regional variation. [24] [25] [26] .
METHODS

Medical centers.
Susceptibility testing. Minimum inhibitory concentrations (MICs) were determined by agar dilution method in accordance with CLSI recommendations [8, 27, 28] . The plates were prepared on the day of the test with use of enriched brucella agar (brucella agar supplemented with 5% lysed defibrinated sheep red blood cells and 1 mg/mL vitamin K). For the preparation of the inocula, the organisms were grown to logarithmic phase, and the turbidity was adjusted to that of a 0.5 McFarland standard (∼ colony-forming units/mL). The inocula were [28, 29] .
Data analysis. Data were stored in Microsoft Excel spreadsheets. Statistical analysis was performed using SAS for Windows, version 8.01 (SAS Institute). Trends for increased or decreased drug resistance over the 10-year study period were determined using the Cochran-Armitage test [30] . Breakpoints for resistance to the antibiotics were those recommended by the CLSI [29] . Breakpoints established by the US Food and Drug Administration for resistance in anaerobes were used for tigecycline [31] . Trends for increased or decreased MICs over time were evaluated using linear regression analysis on the log 10 MIC results. Table 3 shows the distribution, by species, of the 6574 isolates included in the study. B. fragilis continued to be the most frequently isolated species during the 10 years of our study; however, there was a trend toward a reduction in the frequency of isolation from a mean of 52% during the first 8 years to a mean of 48% during the final 2 years, in conjunction with an increase to 52% in the frequency of isolation of the non-B. fragilis Bacteroides species. B. thetaiotaomicron was the second most frequently isolated organism (19.3%). Isolates of B. ovatus comprised 10.3% of the total isolates, and 6% were Bacteriodes vulgatus. Bacteroides caccae, a species previously included among the "other" Bacteroides category, was isolated at higher frequency, similar to that of Bacteriodes distasonis (3.9%) and Bacteroides uniformis (4.4%); thus, it is listed separately during the last 2 years of the study.
RESULTS
Understandably, the majority of blood isolates were B. fragilis. The majority of the nonblood isolates were found in samples from patients with intra-abdominal infection. Table 4 shows a summary of the susceptibilities of 1351 isolates referred from 2005 through 2007. Percent resistance was calculated using breakpoints recommended for the respective antibiotic by the CLSI or Food and Drug Administration [28, 30] . For the carbapenems, low resistance was observed in B. distasonis and B. uniformis. In this class of agents, ertapenem also showed low resistance in B. ovatus and B. thetaiotaomicron. The activity of piperacillin-tazobactam was similar to that of the carbapenems and higher than that of ampicillinsulbactam, which continued to show increased resistance in B. distasonis. Cefoxitin activity against B. distasonis was higher from 2005 through 2007 (11.1%) than it was from 1997 through 2004 (29.9%; data not shown). Resistance of B. ovatus to cefoxitin during this period (∼18%) was similar to that during previous years.
Tigecycline was the most active antibiotic among the nonb-lactam agents (clindamycin, linezolid, tigecycline, moxifloxacin, and trovafloxacin). The highest resistance to tigecycline was observed among the "other" Bacteroides species group. The second most active agent among this group was linezolid, with a resistance ranging from 0% for B. uniformis to 11.2% for B. distasonis and B. ovatus. Resistance of Bacteroides species to clindamycin ranged from 14.3% for B. distasonis to 49.2% for B. uniformis.
More than half of the B. vulgatus isolates were resistant to NOTE. Twenty-seven other Bacteroides species are not included in the table: 14 Bacteroides eggerthii isolates, 4 Bacteroides merdae isolates, 1 Bacteroides nordii isolate, and 8 "other" Bacteroides isolates. Breakpoints for resistance, as recommended by the Clinical and Laboratory Standards Institute were у16 mg/mL for ertapenem, imipenem, and meropenem;
у128 mg/mL for piperacillintazobactam (Pip-Tzb); у32 mg/mL for ampicillin-sulbactam (Amp-Sul);
у64 mg/mL for cefoxitin; and у8 mg/mL for clindamycin, moxifloxacin, and trovafloxacin. The breakpoint for resistance for doripenem was the same as that recommended for other carbapenems (у16 mg/mL), and the breakpoint for resistance for tigecycline was moxifloxacin (56.4%) and trovafloxacin (54.3%). Resistance to these 2 fluoroquinolones increased with time for most of the species. Isolates in the "other" Bacteroides species group (Bacteroides eggerthii, Bacteroides merdae, and Bacteroides nordii) showed a relatively high rate of resistance to tigecycline. In this group, we also observed higher rates of resistance to moxifloxacin (29.6%) and to clindamycin (25.9%).
In general, the MICs required to inhibit the growth of 90% of organisms (MIC 90 ) for the carbapenems, piperacillin-tazobactam, and tigecycline against all the species in the group were below the breakpoints for resistance. By comparison, the MIC 90 of clindamycin, moxifloxacin, and trovafloxacin were equal to or greater than the breakpoint for resistance against all species. In addition, the MIC required to inhibit the growth of 50% of organisms for both fluoroquinolones against B. vulgatus was equal to the resistance breakpoint of 8 mg/mL. The MIC 90 of ampicillin-sulbactam and cefoxitin was equal to the resistance breakpoint against B. distasonis and B. ovatus, respectively. Figure 1A and 1B show the rates of resistance over time (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) From 2002 through 2007, 3 metronidazole-resistant isolates were confirmed in our survey; the first of these was isolated in 2002 [11] . Resistance to metronidazole has been increasingly reported in Europe but not in the United States.
Throughout the survey, specifically from 2003 through 2007, susceptibility to select antibiotics varied by health care center and species. For some antibiotics, such as clindamycin or moxifloxacin, the range of resistance varied greatly by health care center. Analysis of year-to-year variation among health care centers revealed some differences, but most resistance rates remained relatively constant (data not shown).
CONCLUSIONS
The survey provided several insights with respect to susceptibility of Bacteroides species to drugs. Some drugs had constant or increased activity, whereas others had decreased activity against the species. The trends were not always predictable, varying by region and institution. However, some important species-drug susceptibility patterns were found: B. ovatus was more resistant to the carbapenems than were other Bacteroides species, B. vulgatus was more resistant to piperacillin-tazobactam, B. distasonis was more resistant to ampicillin-sulbactam and cefoxitin, B. ovatus and B. uniformis were highly resistant to moxifloxacin, and moxifloxacin resistance rates among B. vulgatus were 150%. "Other" Bacteroides species were more resistant to tigecycline. In general, B. fragilis is more susceptible to antimicrobials than are other Bacteroides species. These data provide a general guide for the clinician in treating anaerobic infections.
The survey should widen its scope in the future. It would be interesting to cover the molecular relatedness of strains. The relationship between antimicrobial use and resistance to these agents would be another important focus. Are fecal isolates more susceptible than clinical isolates? Molecular detection of metronidazole and carbapenem resistance, as well as other genetic markers, is another area of increasing importance. Finally, Internet-based real-time reporting of drug resistance is becoming more widespread and could be applied to the survey.
The anaerobic susceptibility survey has been ongoing for 29 years, thanks in part to the vision of Francis P. Tally ( Figure  2 ). It has evolved and generated an enormous amount of clinically useful microbiological data for the practicing clinician.
